Worldwide sales rose about 18 percent to reach $8.8 billion, fueled in part by strong sales of the drug Humira, which treats rheumatoid arthritis, and a 34 percent rise in global sales of coronary stents, such as Xience. Global stent sales soared to $533 million dollars, the company said.
Abbott expects to hit its previous guidance of full-year earnings of $4.13 to $4.18 per share. The midpoint is a 12 percent increase over 2009.
Ad Statistics
Times Displayed: 134286
Times Visited: 7699 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Abbott rose 1.2 percent to reach $49.25 in recent trading.
Back to HCB News
